Percheron Therapeutics Limited has released a press release.
Percheron Therapeutics: Half Yearly Report and Accounts
Filed with ASX ·
6ix hasn’t read this filing yet.
Percheron Therapeutics Limited on 6ix
Story so far
Earlier from Percheron Therapeutics
- Quarterly Activities/Appendix 4C Cash Flow Report
- Quarterly Activities Report and Appendix 4C
- Percheron Therapeutics Limited to Present at the Life Sciences Virtual Investor Forum September 18th
- Appendix 4E and Annual Report
- Percheron licenses HMBD-002 from Hummingbird Bioscience
Later from Percheron Therapeutics
- Non-renounceable Entitlement Offer
- Prospectus - Non-renounceable Entitlement Offer
- Results of Entitlement Offer
- Percheron Therapeutics Announces CEO Succession
- Vanderbilt Health to conduct clinical trial of HMBD-002
Follow Percheron Therapeutics into a list and get an email when it puts out news.
Follow Percheron Therapeutics